The validation of the mechanism of action of Tiziana Life Sciences' intranasal Foralumab in Alzheimer's disease, and its publication in a reputable journal, following FDA IND clearance, is a significant milestone for the company. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.